KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Free Cash Flow (2019 - 2025)

Royalty Pharma's Free Cash Flow history spans 7 years, with the latest figure at $93.5 million for Q4 2025.

  • For Q4 2025, Free Cash Flow fell 62.02% year-over-year to $93.5 million; the TTM value through Dec 2025 reached $795.0 million, up 201.96%, while the annual FY2025 figure was $792.1 million, 200.85% up from the prior year.
  • Free Cash Flow for Q4 2025 was $93.5 million at Royalty Pharma, down from $702.6 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $772.6 million in Q4 2023 and bottomed at -$1.3 billion in Q3 2021.
  • The 5-year median for Free Cash Flow is $93.5 million (2025), against an average of $82.9 million.
  • The largest annual shift saw Free Cash Flow tumbled 1421.27% in 2021 before it soared 508490.59% in 2023.
  • A 5-year view of Free Cash Flow shows it stood at $318.2 million in 2021, then increased by 0.46% to $319.7 million in 2022, then surged by 141.68% to $772.6 million in 2023, then crashed by 68.15% to $246.1 million in 2024, then crashed by 62.02% to $93.5 million in 2025.
  • Per Business Quant, the three most recent readings for RPRX's Free Cash Flow are $93.5 million (Q4 2025), $702.6 million (Q3 2025), and -$1.1 million (Q1 2025).